Highlights of This Issue 4731

SPECIAL FEATURES

CCR Translations

4733 Prostate Cancer SubtyPINg BiomarkKers and Outcome: Is Clarity EmERGing? Steven C. Smith and Scott A. Tomlins See related article, p. 4904

4737 Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage Karin C. Nitiss and John L. Nitiss See related article, p. 4873

Molecular Pathways

4740 Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

CANCER THERAPY: CLINICAL

4747 Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors Paul Haluska, Michael Meneeeef, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso


4768 The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials A. Schwandt, P.J. Harris, S. Hunsberger, A. Deleporte, G.L. Smith, D. Vulih, B.D. Anderson, and S.P. Ivy

4776 Phase I Study of RBG-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors Diane A.J. van der Biessen, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijssen, and Maja J.A. de Jonge

PERSONALIZED MEDICINE AND IMAGING

4784 A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma Motonobu Saito, Kouya Shiraishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Tauta, Kansuke Kumamoto, Seiichi Takenoshi, Jun Yokota, Curtis C. Harris, and Takashi Kohno

4794 Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Heparocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jiong Wu, Chan-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan

4806 Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortosasco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, and Donald Berry

Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers
Agnieszka K. Witkiewicz, Uthra Balaji, and Erik S. Knudsen

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms
Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale Wallace, Jonathan Friedberg, and Steven Grant

On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, Armando G. Poeppl, James B. Johnston, Spencer B. Gibson, and Versha Banerji

Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard M. Neckers, Hongliang Zhang, and Yves Pommier

Demethylating Drugs as Novel Analgesics for Cancer Pain
Chi T. Viet, Dongmin Dang, Yi Ye, Kentaro Ono, Ronald R. Campbell, and Brian L. Schmidt

SPINK1 Protein Expression and Prostate Cancer Progression
Richard Flavin, Andreas Pettersson, Whitney K. Hendrickson, Michelangelo Fiorentino, Stephen Finn, Lauren Kunz, Gregory L. Judson, Rosina Lis, Dyane Bailey, Christopher Fiore, Elizabeth Nuttall, Neil E. Martin, Edward Stack, Kathryn L. Penney, Jennifer R. Rider, Jennifer Sinnott, Christopher Sweeney, Howard D. Sesso, Katja Fall, Edward Giovannucci, Philip Kantoff, Meir StAMPLer, Massimo Loda, and Lorelei A. Mucci

See related commentary, p. 4733

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Anna Karlsson, Markus Ringnéér, Martin Lauss, Johan Botling, Patrick Micke, Maria Planck, and Johan Staaf

Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Francesca Khani, Juan Miguel Mosquera, Kyung Park, Mirjam Blattner, Catherine O’Reilly, Theresa Y. MacDonald, Zhengming Chen, Abhishek Srivastava, Ashutosh K. Tewari, Christopher E. Barbieri, Mark A. Rubin, and Brian D. Robinson

Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Michael L. Nickerson, Garrett M. Dancik, Kate M. Im, Michael G. Edwards, Sevilay Turan, Joseph Brown, Christina Ruiz-Rodriguez, Charles Owens, James C. Costello, Guangwu Guo, Shirley X. Tsang, Yingrui Li, Quan Zhou, Zhiming Cai, Lee E. Moore, M. Scott Lucia, Michael Dean, and Dan Theodorescu

T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Filipe Pinto, Nélia Pervega-Gomes, Márcia S. Pereira, José R. Vizcaíno, Pedro Monteiro, Rui M. Henrique, Fátima Baltazar, Raquel P. Andrade, and Rui M. Reis

See related commentary, p. 4733
4962  Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study

4971  Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

4972  Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response
Christopher M. Hovens, Matthew K.H. Hong, and Niall M. Corcoran

4974  Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

LETTERS TO THE EDITOR

ABOUT THE COVER
The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.